Literature DB >> 10785256

Prevalence of triplet repeat expansion in ataxia patients from Hokkaido, the northernmost island of Japan.

H Sasaki1, I Yabe, I Yamashita, K Tashiro.   

Abstract

Approximately 44% of cases of spinocerebellar ataxia (SCA) in Hokkaido, the northernmost island of Japan, were estimated to be inherited. To determine the prevalence of triplet repeat expansion in hereditary SCA patients, we genotyped seven genetically defined dominant SCAs in 349 patients, including 266 patients from 77 families, 78 probands from unrelated families with hereditary late-onset SCA, and five patients in whom a family history of SCA was not demonstrated. The frequency of each disorder in a total of 155 unrelated families was 23.9% for Machado-Joseph disease (MJD), 29.0% for SCA6, 9.7% for SCA1, 7.7% for SCA2, and 2.6% for dentatorubral-pallidoluysian atrophy. Abnormal expansion of triplet repeats for SCA7 and SCA8 was not detected. A total of 27.1% of the patients had still unknown SCA mutations. In addition, the GAA repeat in the frataxin gene was not abnormally expanded in 13 early-onset SCA patients with clinical features similar to those of Friedreich ataxia. Comparison of our results with those from other centers handling SCA showed that MJD is prevalent throughout Japan, but the frequencies of other dominant SCAs differ considerably even within Japan.

Entities:  

Mesh:

Year:  2000        PMID: 10785256     DOI: 10.1016/s0022-510x(00)00313-0

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Insights into the mutational history and prevalence of SCA1 in the Indian population through anchored polymorphisms.

Authors:  Uma Mittal; Sangeeta Sharma; Rupali Chopra; Kalladka Dheeraj; Pramod Kr Pal; Achal K Srivastava; Mitali Mukerji
Journal:  Hum Genet       Date:  2005-10-28       Impact factor: 4.132

2.  Spectrum and prevalence of autosomal dominant spinocerebellar ataxia in Hokkaido, the northern island of Japan: a study of 113 Japanese families.

Authors:  Rehana Basri; Ichiro Yabe; Hiroyuki Soma; Hidenao Sasaki
Journal:  J Hum Genet       Date:  2007-09-05       Impact factor: 3.172

Review 3.  Spinocerebellar ataxia type 8 in Scotland: genetic and clinical features in seven unrelated cases and a review of published reports.

Authors:  A Zeman; J Stone; M Porteous; E Burns; L Barron; J Warner
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-03       Impact factor: 10.154

4.  A clinical and genetic study in a large cohort of patients with spinocerebellar ataxia type 6.

Authors:  Hiroki Takahashi; Kinya Ishikawa; Takeshi Tsutsumi; Hiroto Fujigasaki; Akihiro Kawata; Ryoichi Okiyama; Tsuneo Fujita; Kazuo Yoshizawa; Shigeki Yamaguchi; Hitoshi Tomiyasu; Fumihito Yoshii; Kazuko Mitani; Natsue Shimizu; Mineo Yamazaki; Tomoyuki Miyamoto; Tomoyuki Orimo; Shin'ichi Shoji; Ken Kitamura; Hidehiro Mizusawa
Journal:  J Hum Genet       Date:  2004       Impact factor: 3.172

5.  Friedreich Ataxia: Diagnostic Yield and Minimal Frequency in South Brazil.

Authors:  Helena Fussiger; Maria Luiza Saraiva-Pereira; Sandra Leistner-Segal; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2019-02       Impact factor: 3.847

6.  An adult form of Alexander disease: a novel mutation in glial fibrillary acidic protein.

Authors:  K Ohnari; M Yamano; T Uozumi; T Hashimoto; S Tsuji; M Nakagawa
Journal:  J Neurol       Date:  2007-10-15       Impact factor: 4.849

7.  The First Case of Spinocerebellar Ataxia Type 8 in Monozygotic Twins.

Authors:  Jun Sawada; Takayuki Katayama; Takashi Tokashiki; Shiori Kikuchi; Kohei Kano; Kae Takahashi; Tsukasa Saito; Yoshiki Adachi; Yuji Okamoto; Akiko Yoshimura; Hiroshi Takashima; Naoyuki Hasebe
Journal:  Intern Med       Date:  2019-09-26       Impact factor: 1.271

8.  Ataxia with Oculomotor Apraxia Type 1 without Oculomotor Apraxia: A Case Report.

Authors:  Minwoo Lee; Nan Young Kim; Jin Young Huh; Young Eun Kim; Yun Joong Kim
Journal:  J Clin Neurol       Date:  2015-11-04       Impact factor: 3.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.